Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Portola Pharmaceuticals Inc.

www.portola.com

Latest From Portola Pharmaceuticals Inc.

Pipeline Watch: Phase III Starts With Fitusiran In Hemophilia, Zoliflodacin In Gonorrhea, Opdivo Combo In RCC

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

NME Mid-Year Report: Approvals Might Near Record With Strong 2nd Half

CDER approved 23 new drugs in the first half of 2017, topping the 22 approved in all 2016; there are at least 18 products in CDER's pipeline with a user fee date this year.

Drug Review Regulation

Biopharma Stocks June 2017: BIO’s Rallying Cry Gets A Response

In this month’s stock column, after the Nasdaq Biotech Index (NBI) shot up over 10% at end of June, Scrip focuses on the biopharma companies that propelled that surge. It looks as if investors have been influenced by the BIO Convention held in San Diego, the industry’s biggest forum for self-promotion.

Financing Analysis

Pipeline Watch: Phase III Progress With Anacetrapib, ALKS 3831 And LentiGlobin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Portola Pharmaceuticals Inc.
  • Senior Management
  • William Lis, CEO
    Mardi C Dier, EVP, CFO
    John T Curnutte, MD, PhD, EVP, R&D
    Tao Fu, EVP, Chief Commercial & Bus. Officer
  • Contact Info
  • Portola Pharmaceuticals Inc.
    Phone: (650) 246-7000
    270 E. Grand Ave.
    So. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register